Navigation Links
Sapio Sciences Announces Exemplar Dx LIMS for Laboratories in the Burgeoning MDx Market
Date:1/31/2012

BALTIMORE, Jan. 31, 2012 /PRNewswire/ -- Sapio Sciences (http://www.SapioSciences.com) is pleased to announce the immediate availability of Exemplar Dx LIMS. This release is the result of Sapio's extensive experience in implementing LIMS at leading MDx companies. Exemplar Dx LIMS addresses MDx companies' operational needs in a single, integrated solution.

The MDx Market

The molecular diagnostics market is experiencing rapid growth largely due to advances in genetics/genomics/proteomics technologies over the last decade that have enabled significant discoveries to be made in predictive biology. Many commercial companies are emerging with new tests in combination with proprietary algorithms to make useful predictions for patients, such as which drug to take for a particular cancer. In order to commercialize these tests, a Molecular Dx company will typically establish a lab for sample processing and assessment. For US based labs to conform to regulations, the entire process from sample receipt to sample processing needs to be compliant with CLIA regulations.

MDx Company Requirements

Molecular Dx labs have a diverse set of information technology needs that span well beyond what is traditionally thought of as "Lab Information Management." All or some of the following are often needed:

  • An ordering system for physicians to enter test requests
  • Collection Kit Management
  • Pathology Lab Interfaces
  • Sample Management/Lab Workflow Tracking – Electronic Lab Notebook
  • Instrument Integrations for Lab Automation
  • Assay Data Management
  • Custom Algorithm Implementation
  • Automated Diagnostic Report Creation with E-signature
  • Medical Billing
  • HL7 Support, CLIA compliance, validated

Exemplar Dx LIMS addresses each of these needs while allowing for configuration\customization to meet each company's specific requirements.

MDx Test Reimbursement

MDx companies need to handle the collection and processing of payment information for their tests. The payment processing is typically done with a third party provider who specializes in billing for these new tests. As insurance companies and Medicare are still becoming familiar with molecular tests, having a billing provider who is experienced in working with these agencies is critically important to getting proper reimbursement.

Sapio is pleased to announce that as part of the Exemplar Dx LIMS offering that we have selected GGB Medical Management as our preferred billing provider. Exemplar Dx LIMS has a pre-built, automated integration between Exemplar and GGB's information systems that ensures proper and timely data transfer. "GGB has extensive experience handling the billing needs of the MDx market, which requires a deep understanding of the evolving regulations to ensure proper processing and reimbursement in a timely fashion," says Rob Gerstien, president GGB. "We have already worked with Sapio and their Exemplar product for MDx products at a leading MDx company and found their team and technology to be top tier. We are enthused to be partnering with them and to be providing a comprehensive solution for the growing molecular diagnostics market."

"The Exemplar Dx LIMS product release is the culmination of years of experience working with leading MDx companies who are bringing their new tests to market. Now, for the first time, MDx companies can get a single solution that addresses everything from the original test request through its processing and results delivery to the test requestor in a fully electronic, automated pipeline," says Kevin Cramer, VP of Sales and Marketing at Sapio.

Kevin continues, "We are also excited to be formalizing our relationship with GGB who we have worked with previously and found their technology platform straightforward to integrate with Exemplar for automated information transfer. Just as important is that GGB has demonstrated expertise in getting reimbursement for their clients, which can be challenging with these new molecular based tests."

For more information, or to schedule a product demonstration, visit http://www.SapioSciences.com.
For more on GGB visit: www.ggbmedical.com 


'/>"/>
SOURCE Sapio Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
Breaking Medicine Technology:
(Date:2/12/2016)... MIAMI, FLA (PRWEB) , ... February 12, 2016 , ... ... free dental implants to their Miami dental office. Beginning in January, Miami Dental ... traditional titanium. Miami Dental Specialists are the first office to be chosen by the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today ... , The print component of “Revolutionizing Cancer Care” is distributed within the February ... and Seattle, with a circulation of approximately 250,000 copies and an estimated readership ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have ... possibilities. CertainTeed, North America’s leading brand of building products, has improved upon its ... in the mobile version of the ColorView® Exterior Style and Color Selector. Created ...
(Date:2/12/2016)... ... 12, 2016 , ... Healthcare careers in the medical laboratory, nursing, and in ... website of healthcare staffing leader Aureus Medical Group during the month of January. Aureus ... therapy positions and in travel and direct hire opportunities in other allied health ...
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... real facts surrounding all those Bible stories. For generations families have gathered to hear ... says there is more to these than just mere “stories”. , The article ...
Breaking Medicine News(10 mins):